Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

9.990 +0.180 (+1.83%)
Streaming Delayed Price Updated: 1:33 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Assembly Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 – 
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Announces $12.6 Million in Equity Financings
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Announces Effective Date of Reverse Stock Split
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Provides Anticipated Development Milestones for 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
From Assembly Biosciences, Inc.
Via GlobeNewswire
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
From Gilead Sciences, Inc.
Via Business Wire
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
From Assembly Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.